Dehydroepiandrosterone and cardiac allograft vasculopathy

D. M. Herrington, N. Nanjee, S. C. Achuff, D. E. Cameron, B. Dobbs, K. L. Baughman

Research output: Contribution to journalArticle

Abstract

Background: Tissue culture, animal model, and epidemiologic studies suggest that dehydroepiandrosterone may inhibit atherosclerosis through its potent antiproliferative effects. Because cardiac allograft vasculopathy is predominantly a proliferative abnormality of intimal and medial smooth muscle cells, plasma levels of dehydroepiandrosterone may play an important role in the development of this disease. Methods: Sixty-one cardiac allograft recipients who survived for 1 year or more and had at least one annual follow-up cardiac catheterization were included in the study. Plasma levels of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and free dehydroepiandrosterone (dehydroepiandrosterone not bound to sex hormone- binding globulin) were measured in all 61 subjects and compared with the presence or absence of cardiac allograft vasculopathy as defined by angiography. Results: Plasma levels of total and free dehydroepiandrosterone were lower in subjects in whom cardiac allograft vasculopathy developed (p = 0.005 and 0.003, respectively). Furthermore, the time to development of cardiac allograft vasculopathy was shorter in subjects with low levels of total and free dehydroepiandrosterone (p = 0.062 and 0.040, respectively). This relationship was maintained after adjusting for age, gender, cholesterol, prednisone use, and blood pressure. Conclusions: Low plasma levels of dehydroepiandrosterone may facilitate and high levels may retard the development of cardiac allograft vasculopathy.

LanguageEnglish (US)
Pages88-93
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume15
Issue number1 I
StatePublished - 1996
Externally publishedYes

Fingerprint

Dehydroepiandrosterone
Allografts
Tunica Intima
Sex Hormone-Binding Globulin
Dehydroepiandrosterone Sulfate
Cardiac Catheterization
Prednisone
Smooth Muscle Myocytes
Epidemiologic Studies
Atherosclerosis
Angiography
Animal Models
Cholesterol
Blood Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Herrington, D. M., Nanjee, N., Achuff, S. C., Cameron, D. E., Dobbs, B., & Baughman, K. L. (1996). Dehydroepiandrosterone and cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 15(1 I), 88-93.

Dehydroepiandrosterone and cardiac allograft vasculopathy. / Herrington, D. M.; Nanjee, N.; Achuff, S. C.; Cameron, D. E.; Dobbs, B.; Baughman, K. L.

In: Journal of Heart and Lung Transplantation, Vol. 15, No. 1 I, 1996, p. 88-93.

Research output: Contribution to journalArticle

Herrington, DM, Nanjee, N, Achuff, SC, Cameron, DE, Dobbs, B & Baughman, KL 1996, 'Dehydroepiandrosterone and cardiac allograft vasculopathy' Journal of Heart and Lung Transplantation, vol 15, no. 1 I, pp. 88-93.
Herrington DM, Nanjee N, Achuff SC, Cameron DE, Dobbs B, Baughman KL. Dehydroepiandrosterone and cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation. 1996;15(1 I):88-93.
Herrington, D. M. ; Nanjee, N. ; Achuff, S. C. ; Cameron, D. E. ; Dobbs, B. ; Baughman, K. L./ Dehydroepiandrosterone and cardiac allograft vasculopathy. In: Journal of Heart and Lung Transplantation. 1996 ; Vol. 15, No. 1 I. pp. 88-93
@article{bef93276adcb46cab7fc0451fe762345,
title = "Dehydroepiandrosterone and cardiac allograft vasculopathy",
abstract = "Background: Tissue culture, animal model, and epidemiologic studies suggest that dehydroepiandrosterone may inhibit atherosclerosis through its potent antiproliferative effects. Because cardiac allograft vasculopathy is predominantly a proliferative abnormality of intimal and medial smooth muscle cells, plasma levels of dehydroepiandrosterone may play an important role in the development of this disease. Methods: Sixty-one cardiac allograft recipients who survived for 1 year or more and had at least one annual follow-up cardiac catheterization were included in the study. Plasma levels of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and free dehydroepiandrosterone (dehydroepiandrosterone not bound to sex hormone- binding globulin) were measured in all 61 subjects and compared with the presence or absence of cardiac allograft vasculopathy as defined by angiography. Results: Plasma levels of total and free dehydroepiandrosterone were lower in subjects in whom cardiac allograft vasculopathy developed (p = 0.005 and 0.003, respectively). Furthermore, the time to development of cardiac allograft vasculopathy was shorter in subjects with low levels of total and free dehydroepiandrosterone (p = 0.062 and 0.040, respectively). This relationship was maintained after adjusting for age, gender, cholesterol, prednisone use, and blood pressure. Conclusions: Low plasma levels of dehydroepiandrosterone may facilitate and high levels may retard the development of cardiac allograft vasculopathy.",
author = "Herrington, {D. M.} and N. Nanjee and Achuff, {S. C.} and Cameron, {D. E.} and B. Dobbs and Baughman, {K. L.}",
year = "1996",
language = "English (US)",
volume = "15",
pages = "88--93",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "1 I",

}

TY - JOUR

T1 - Dehydroepiandrosterone and cardiac allograft vasculopathy

AU - Herrington,D. M.

AU - Nanjee,N.

AU - Achuff,S. C.

AU - Cameron,D. E.

AU - Dobbs,B.

AU - Baughman,K. L.

PY - 1996

Y1 - 1996

N2 - Background: Tissue culture, animal model, and epidemiologic studies suggest that dehydroepiandrosterone may inhibit atherosclerosis through its potent antiproliferative effects. Because cardiac allograft vasculopathy is predominantly a proliferative abnormality of intimal and medial smooth muscle cells, plasma levels of dehydroepiandrosterone may play an important role in the development of this disease. Methods: Sixty-one cardiac allograft recipients who survived for 1 year or more and had at least one annual follow-up cardiac catheterization were included in the study. Plasma levels of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and free dehydroepiandrosterone (dehydroepiandrosterone not bound to sex hormone- binding globulin) were measured in all 61 subjects and compared with the presence or absence of cardiac allograft vasculopathy as defined by angiography. Results: Plasma levels of total and free dehydroepiandrosterone were lower in subjects in whom cardiac allograft vasculopathy developed (p = 0.005 and 0.003, respectively). Furthermore, the time to development of cardiac allograft vasculopathy was shorter in subjects with low levels of total and free dehydroepiandrosterone (p = 0.062 and 0.040, respectively). This relationship was maintained after adjusting for age, gender, cholesterol, prednisone use, and blood pressure. Conclusions: Low plasma levels of dehydroepiandrosterone may facilitate and high levels may retard the development of cardiac allograft vasculopathy.

AB - Background: Tissue culture, animal model, and epidemiologic studies suggest that dehydroepiandrosterone may inhibit atherosclerosis through its potent antiproliferative effects. Because cardiac allograft vasculopathy is predominantly a proliferative abnormality of intimal and medial smooth muscle cells, plasma levels of dehydroepiandrosterone may play an important role in the development of this disease. Methods: Sixty-one cardiac allograft recipients who survived for 1 year or more and had at least one annual follow-up cardiac catheterization were included in the study. Plasma levels of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and free dehydroepiandrosterone (dehydroepiandrosterone not bound to sex hormone- binding globulin) were measured in all 61 subjects and compared with the presence or absence of cardiac allograft vasculopathy as defined by angiography. Results: Plasma levels of total and free dehydroepiandrosterone were lower in subjects in whom cardiac allograft vasculopathy developed (p = 0.005 and 0.003, respectively). Furthermore, the time to development of cardiac allograft vasculopathy was shorter in subjects with low levels of total and free dehydroepiandrosterone (p = 0.062 and 0.040, respectively). This relationship was maintained after adjusting for age, gender, cholesterol, prednisone use, and blood pressure. Conclusions: Low plasma levels of dehydroepiandrosterone may facilitate and high levels may retard the development of cardiac allograft vasculopathy.

UR - http://www.scopus.com/inward/record.url?scp=0030022179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030022179&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 88

EP - 93

JO - Journal of Heart and Lung Transplantation

T2 - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 1 I

ER -